Pharmacologic treatments for covid-19 patients

Tocilizumab vs Standard care/Placebo

On March 18th, 2021, we published results of the living systematic review on IL-6 blocking agents which included all preprints and published trials published online up to February 11th, 2021.


Hospitalized patients

Forest plots
(last update: 2022-05-16)

Funnel plots
(last update: 2022-04-03)

Summary of findings
(last update: 2022-04-27)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=28

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04330638; EudraCT2020-001500-41
COV-AID
Declercq J, Lancet Respir Med, 2021
Full text
Commentary
Commentary
(21)00405-7
Public/non profit

Anakinra

Tocilizumab

Siltuximab

Anakinra

Anakinra

Tocilizumab

Anakinra + Tocilizumab

Standard care

Standard care

Standard care

Tocilizumab

Siltuximab

Siltuximab

Standard care

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 16 centers in Belgium. N=342
Some concerns
Details

Full description

NCT04377750
HMO-0224-20
HMO-0224-20, Unpublished, 2021
Public/non profit

Tocilizumab

Placebo

RCT Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in Israel. N=54
High
Details

Full description

NCT04332094, EudraCT 2020-001442-19
TOCOVID
TOCOVID, Unpublished, 2021
Public/non profit

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19(mild-moderate) admitted to multiple centers in Spain. N=270
Low
Details

Full description

NCT04412291, EudraCT 2020-001748-24
IMMCOVA
IMMCOVA, Unpublished, 2021
Public/non profit

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a multiple centerd in Sweden N=49
Low
Details

Full description

NCT04435717
COVITOZ-01
COVITOZ-01, Unpublished, 2021
Public/non profit

Tocilizumab

Standard care

RCT Patients with suspected or confirmed COVID-19 (mild-moderate-severe) admitted to a single center in Spain. N=26
Low
Details

Full description

NCT04577534
COVIDSTORM
Broman N, Clin Microbiol Infect, 2022
Full text
Commentary
No specific funding

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Finland. N=88
Some concerns
Details

Full description

NCT04409262
REMDACTA
Rosas, IO, Intensive Care Med, 2021
Full text
Commentary
Private

Tocilizumab

Placebo

RCT Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in Spain, USA, Brazil and Russia. N=649
Some concerns
Details

Full description

NCT04479358
COVIDOSE-2
COVIDOSE-2, Unpublished, 2021
Public/non profit

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to multiple centers in the USA N=28
Low
Details

Full description

NCT04331808
CORIMUNO-TOCI-2
Hermine O, Eur Respir J, 2022 a
Full text
Commentary
Public/non profit

Tocilizumab

Standard care

RCT Patients with suspected or confirmed COVID-19 (severe-critical) admitted to 12 centers in France. N=97
Some concerns
Details

Full description

NCT04412772
ARCHITECTS
ARCHITECTS, Unpublished, 2021
Public/non profit

Tocilizumab

Placebo

RCT Patients with confirmed COVID-19 (critical) admitted to a single center in the USA. N=21
Low
Details

Full description

NCT04330638
COV-AID
COV-AID, Unpublished, 2021
Public/non profit

Tocilizumab

Standard care

RCT Patients with suspected or confirmed COVID-19 (severe-critical) admitted to 16 centers in Belgium N=153
Low
Details

Full description

NCT02735707
REMAP-CAP
Derde L, medRxiv, 2021
Full text
Commentary
Commentary
Mixed

Tocilizumab

Sarilumab

Anakinra

Standard care

RCT Patients with suspected or confirmed COVID-19 (moderate to critical) admitted to 133 centers in 9 countries N=2253
Some concerns
Details

Full description

IRCT20081027001411N4
Talaschian M, Research Square, 2021
Full text
Commentary
Commentary
Public/non profit

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran N=40
High
Details

Full description

Trial NL8504
Rutgers A, SSRN, 2021
Full text
Commentary
Mixed

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 11 centers in the Netherlands. N=354
Some concerns
Details

Full description

CTRI/2020/05/025369
COVINTOC
Soin AS, Lancet Respir Med, 2021
Full text
Commentary
Mixed

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 12 centers in India N=180
Some concerns
Details

Full description

NCT04381936, ISRCTN50189673
RECOVERY (TCZ)
Horby P, Lancet, 2021
Full text
Commentary
Commentary
Public/non profit

Tocilizumab

Standard care

RCT Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 131 centers in the UK N=4116
Some concerns
Details

Full description

NCT04403685
TOCIBRAS
Veiga VC, BMJ, 2021
Full text
Commentary
Commentary
Mixed

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 9 centers in Brazil N=129
Some concerns
Details

Full description

NCT02735707
REMAP-CAP
Gordon AC, N Engl J Med, 2021
Full text
Full text
Commentary
Commentary
Mixed

Tocilizumab

Sarilumab

Standard care

RCT Patients with confirmed or suspected COVID-19 (severe-critical) admitted to 113 centers in Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK. N=826
Some concerns
Details

Full description

NCT04372186
EMPACTA
Salama C, N Engl J Med, 2020
Full text
Full text
Commentary
Commentary
Private

Tocilizumab

Placebo

RCT Patients with confirmed COVID-19 (mild-severe) admitted to 65 centers in Brazil, Kenya, Mexico, Peru, South Africa, and USA N=388
Some concerns
Details

Full description

NCT04356937
Stone JH, N Engl J Med, 2020
Full text
Commentary
Private

Tocilizumab

Placebo

RCT Patients with COVID-19 (mild-severe) admitted to seven centers in USA N=243
Low
Details

Full description

NCT04331808
CORIMUNO-19
Hermine O, JAMA Intern Med, 2020
Full text
Commentary
Public/non profit

Tocilizumab

Standard care

RCT Patients with COVID-19 (moderate-severe) admitted to nine centers in France N=131
Some concerns
Details

Full description

NCT04346355
Salvarani C, JAMA , 2020
Full text
Commentary
Mixed

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19 (severe) admitted to 24 centers in Italy N=126
Some concerns
Details

Full description

ChiCTR2000029765
Wang D, Front Med, 2021
Full text
Full text
Commentary
Public/non profit

Tocilizumab

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in China N=65
Some concerns
Details

Full description

NCT04320615
COVACTA
Rosas I, N Engl J Med, 2021
Full text
Commentary
Mixed

Tocilizumab

Placebo

RCT Patients with confirmed COVID-19 (mild-critical) admitted to multiple centers across 9 countries N=452
Low
Details

Full description